<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H572CE97E81C94CE7827C6DB47DB08C8D" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>116 HR 8467 IH: Access to Rare Indications Act of 2020</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2020-09-30</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">116th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 8467</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20200930">September 30, 2020</action-date><action-desc><sponsor name-id="T000460">Mr. Thompson of California</sponsor> (for himself and <cosponsor name-id="K000376">Mr. Kelly of Pennsylvania</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend titles XVIII and XIX of the Social Security Act and title XXVII of the Public Health Service Act to provide for coverage of certain drugs used in the treatment or management of a rare disease or condition, and for other purposes.</official-title></form><legis-body id="H31BC3AB185BB4056B4911B0C1033B000" style="OLC"><section id="H92B3DBBCD836452DB2BD546D04C32C57" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Access to Rare Indications Act of 2020</short-title></quote>.</text></section><section id="H86371E3CD3CA4AA39A90792F48A5A51E" section-type="subsequent-section"><enum>2.</enum><header>Coverage of certain drugs used in treatment or management of rare disease or condition</header><subsection id="HB599CE40D7E14A19B8A15382196C1A56"><enum>(a)</enum><header>Medicare</header><paragraph id="H7C890F04427645C7864ACB49D36F62DA"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Section 1861(t)(2) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">42 U.S.C. 1395x(t)(2)</external-xref>) is amended—</text><subparagraph id="H67831462E147424B8FEDA3A9AE77EE2E"><enum>(A)</enum><text>in subparagraph (A), by inserting after <quote>regimen</quote> the following: <quote>, or in the treatment or management of a disease or condition affecting 200,000 or fewer individuals in the United States,</quote>; and</text></subparagraph><subparagraph id="HBF30BBB816D347EEBE86353C8E55589F"><enum>(B)</enum><text>in subparagraph (B)(ii)—</text><clause id="HE7F53640B0E04679BAAC4F2CD96C9FEA"><enum>(i)</enum><text>in subclause (I), by striking <quote>, or</quote> at the end and inserting a semicolon;</text></clause><clause id="H6BF1571E69B646408B80866271F9C00F"><enum>(ii)</enum><text>in subclause (II), by striking the period at the end and inserting <quote>; or</quote>; and</text></clause><clause id="H45FED97E57DF4171AC2A2BD0CF00804A"><enum>(iii)</enum><text>by adding at the end the following new subclause:</text><quoted-block style="OLC" id="H2F0AD3147A5640D98FE41A265D56808D" display-inline="no-display-inline"><subclause id="HFC33283756274B7CA3F225F477F83668" indent="up3"><enum>(III)</enum><text display-inline="yes-display-inline">in the case that the drug is used in the treatment or management of a disease or condition affecting 200,000 or fewer individuals in the United States, such use is supported by peer-reviewed literature, clinical guidelines, or expert opinion within the National Institutes of Health Rare Diseases Clinical Research Network consortia or its participating clinical centers.</text></subclause><after-quoted-block>.</after-quoted-block></quoted-block></clause></subparagraph></paragraph><paragraph id="H94174852FAA043BCBAD23D58FEEDBF7D"><enum>(2)</enum><header>Prohibition of coverage exclusions for formularies under Medicare part D</header><text>Section 1860D–4(b)(3) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-104">42 U.S.C. 1395w–104(b)(3)</external-xref>) is amended by adding at the end the following new subparagraph:</text><quoted-block style="OLC" id="HF927C7F0BC654B27B387BCA2BAB520D8" display-inline="no-display-inline"><subparagraph id="HCEC0B07FBC9F48E282404B5B07D778CE"><enum>(I)</enum><header>Prohibition of certain coverage exclusions</header><clause id="H32E6DE9F077741AABAC3D3B3CB37EDB3"><enum>(i)</enum><header>In general</header><text display-inline="yes-display-inline">If the PDP sponsor of a prescription drug plan uses a formulary, such sponsor may not impose a limitation or exclusion of benefits with respect to coverage of a rare disease covered part D drug (as defined in clause (ii)) included in such formulary.</text></clause><clause id="HD8C49DDE239540EB92422A7F0BDF0441"><enum>(ii)</enum><header>Rare disease covered part D drug</header><text>For purposes of this subparagraph, the term <quote>rare disease covered part D drug</quote> means a covered part D drug—</text><subclause id="H68D693F9EC1B4C5B93CABF660C29F0EC"><enum>(I)</enum><text display-inline="yes-display-inline">used in the treatment or management of a disease or condition affecting 200,000 or fewer individuals in the United States; and</text></subclause><subclause id="HB81ACEA87BB7481FA710456847366850"><enum>(II)</enum><text display-inline="yes-display-inline">the use of which is supported by peer-reviewed literature, clinical guidelines, or expert opinion within the National Institutes of Health Rare Diseases Clinical Research Network consortia or its participating clinical centers.</text></subclause></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph id="H039AAA7285EB43A18D20ED0531B7EB4D"><enum>(3)</enum><header>Effective date</header><text>The amendments made by this subsection apply with respect to items and services furnished on or after the date that is 30 days after the date of the enactment of this Act.</text></paragraph></subsection><subsection id="H5A476365E1AA49B698D60B9AC69B594A"><enum>(b)</enum><header>Medicaid</header><paragraph id="H18DFEBE0CC1E4EDD860E275976A9A462"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Section 1927(k)(6) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396r-8">42 U.S.C. 1396r–8(k)(6)</external-xref>) is amended—</text><subparagraph id="HD9DFDD3BF86244DC9B3FE0AE0CEBE38B"><enum>(A)</enum><text>by striking <quote>, or</quote> and inserting a comma; and</text></subparagraph><subparagraph id="H6E7F979CFB944936B002FA1BA2391FC1"><enum>(B)</enum><text>by inserting before the period the following: <quote>, or the use of which is related to the treatment or management of a disease or condition affecting 200,000 or fewer individuals in the United States and is supported by peer-reviewed literature, clinical guidelines, or expert opinion within the National Institutes of Health Rare Diseases Clinical Research Network consortia or its participating clinical centers</quote>.</text></subparagraph></paragraph><paragraph id="HE90166737D9F44B3AF3C1DDB8B382418"><enum>(2)</enum><header>Prohibition of coverage exclusions for formularies</header><text>Section 1927(d)(4) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396r-8">42 U.S.C. 1396r–8(d)(4)</external-xref>) is amended—</text><subparagraph id="H8CAAA10C2D154743B44BA2296E6047EB"><enum>(A)</enum><text>in subparagraph (C), by striking <quote>A covered outpatient drug</quote> and inserting <quote>Subject to subparagraph (E), a covered outpatient drug</quote>;</text></subparagraph><subparagraph id="HE97477F7A06945B88A99FB7F48E6AB15"><enum>(B)</enum><text>by redesignating subparagraph (E) as subparagraph (F); and</text></subparagraph><subparagraph id="H9F77310E425A442FA8850A98B31D65C5"><enum>(C)</enum><text>by inserting after subparagraph (D) the following new subparagraph:</text><quoted-block style="OLC" id="HDDCA7684BC614688A91FAACA32198492" display-inline="no-display-inline"><subparagraph id="HD2D0BD711C5149CB94735D443AE9873C"><enum>(E)</enum><text display-inline="yes-display-inline">Notwithstanding subparagraph (C), the State may not impose a limitation or exclusion of benefits with respect to coverage of a covered outpatient drug that is—</text><clause id="H7C4FD95BD3AE46329EF589CA27757EB1"><enum>(i)</enum><text>used in the treatment or management of a disease or condition affecting 200,000 or fewer individuals in the United States; and</text></clause><clause id="HBD532ED5DA7C47E0959C4BCD3798B21A"><enum>(ii)</enum><text>the use of which is supported by peer-reviewed literature, clinical guidelines, or expert opinion within the National Institutes of Health Rare Diseases Clinical Research Network consortia or its participating clinical centers.</text></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="H4E59DF14D3B041E19E4F2F06613C88B0"><enum>(3)</enum><header>Effective date</header><text>The amendments made by this subsection apply with respect to covered outpatient drugs furnished on or after the date that is 30 days after the date of the enactment of this Act.</text></paragraph></subsection><subsection id="H2D56C1C50C374A48885BE62ABC5CEA30"><enum>(c)</enum><header>Private health insurance</header><paragraph id="H8AF058A4A08F4BF999A806C5B1B63F56"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Subpart II of part A of title XXVII of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300gg-11">42 U.S.C. 300gg–11</external-xref> et seq.) is amended by adding at the end the following new section:</text><quoted-block style="OLC" id="H09B85020C97F44AEA352322F8927954E" display-inline="no-display-inline"><section id="H64636563DB134237ABF0B2CCD31CDA56"><enum>2730.</enum><header>Coverage of certain drugs used in treatment or management of rare disease or condition</header><subsection id="HD21E6A54DCFD46FDA33AA2EB2759D109"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">A group health plan or a health insurance issuer offering group or individual health insurance coverage shall provide coverage for a drug—</text><paragraph id="H5A123121F71A4A01867A82DA4EA889C8"><enum>(1)</enum><text>approved by the Food and Drug Administration;</text></paragraph><paragraph id="H565821BE3EF341A3818CC1BF1246CFED"><enum>(2)</enum><text display-inline="yes-display-inline">used in the treatment or management of a disease or condition affecting 200,000 or fewer individuals in the United States; and</text></paragraph><paragraph id="HECD9BE2CAF694D98812F63D5C82DDB87"><enum>(3)</enum><text>the use of which is supported by peer-reviewed literature, clinical guidelines, or expert opinion within the National Institutes of Health Rare Diseases Clinical Research Network consortia or its participating clinical centers.</text></paragraph></subsection><subsection id="HBD589E22A94D493095BDC7606BDD176A" commented="no"><enum>(b)</enum><header>Prohibition of certain coverage exclusions</header><text display-inline="yes-display-inline">A group health plan or a health insurance issuer offering group or individual health insurance coverage may not impose a limitation or exclusion of benefits with respect to coverage of a drug described in subsection (a) other than a limitation or exclusion of benefits with respect to a use of such drug identified as contraindicated by the Food and Drug Administration.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph id="HB2A8D6D810A74EC298B6AEB18CBCC0E2"><enum>(2)</enum><header>Effective date</header><text>The amendment made by this subsection applies with respect to plan years beginning on or after the date that is 30 days after the date of the enactment of this Act.</text></paragraph></subsection></section></legis-body></bill> 

